OC Oerlikon Corporation AG (FRA:OBH)

Theseus Pharmaceuticals Balance Sheet

Financials in millions CHF. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	176	398	524	463	601	414
Short-Term Investments	4	14	16	13	18	15
Cash & Short-Term Investments	180	412	540	476	619	429
Cash Growth	-48.13%	-23.70%	13.44%	-23.10%	44.29%	-38.36%
Accounts Receivable	320	415	433	472	525	341
Other Receivables	64	96	94	117	148	124
Receivables	384	511	527	589	673	465
Inventory	282	411	395	504	407	310
Prepaid Expenses	24	17	19	24	26	25
Other Current Assets	921	3	5	4	9	4
Total Current Assets	1,791	1,354	1,486	1,597	1,734	1,233
Property, Plant & Equipment	523	669	677	705	792	771
Long-Term Investments	19	35	36	42	41	30
Goodwill	-	965	949	785	815	562
Other Intangible Assets	1,240	650	686	568	623	468
Long-Term Accounts Receivable	-	1	2	6	5	-
Long-Term Deferred Tax Assets	70	153	134	117	145	139
Long-Term Deferred Charges	-	101	94	92	100	105
Other Long-Term Assets	21	45	-	-1	56	19
Total Assets	3,681	4,002	4,099	3,937	4,341	3,340
Accounts Payable	108	340	296	400	355	284
Accrued Expenses	145	233	259	258	235	201
Short-Term Debt	62	13	-	151	13	8
Current Portion of Long-Term Debt	470	250	-	-	124	-
Current Portion of Leases	30	33	31	29	31	31
Current Income Taxes Payable	21	45	39	43	56	47
Current Unearned Revenue	20	182	205	359	549	415
Other Current Liabilities	718	150	321	222	159	136
Total Current Liabilities	1,574	1,246	1,151	1,462	1,522	1,122
Long-Term Debt	793	1,049	1,310	604	611	157
Long-Term Leases	157	172	178	163	181	175
Long-Term Deferred Tax Liabilities	139	171	167	130	171	125
Other Long-Term Liabilities	32	36	57	53	99	63
Total Liabilities	2,761	2,867	3,061	2,621	2,872	1,988
Common Stock	340	340	340	340	340	340
Additional Paid-In Capital	558	558	558	558	558	558
Retained Earnings	660	779	718	812	837	712
Treasury Stock	-118	-125	-129	-134	-120	-123
Comprehensive Income & Other	-533	-434	-477	-302	-191	-163
Total Common Equity	907	1,118	1,010	1,274	1,424	1,324
Minority Interest	13	17	28	42	45	28
Shareholders' Equity	920	1,135	1,038	1,316	1,469	1,352
Total Liabilities & Equity	3,681	4,002	4,099	3,937	4,341	3,340
Total Debt	1,512	1,517	1,519	947	960	371
Net Cash (Debt)	-1,332	-1,105	-979	-471	-341	58
Net Cash Growth	-	-	-	-	-	-82.58%
Net Cash Per Share	-4.04	-3.40	-3.02	-1.45	-1.04	0.18
Filing Date Shares Outstanding	336	325.39	324.93	324.38	326.64	325.82
Total Common Shares Outstanding	336	325.39	324.93	324.38	326.64	325.82
Working Capital	217	108	335	135	212	111
Book Value Per Share	2.70	3.44	3.11	3.93	4.36	4.06
Tangible Book Value	-333	-497	-625	-79	-14	294
Tangible Book Value Per Share	-0.99	-1.53	-1.92	-0.24	-0.04	0.90
Land	-	30	32	33	34	35
Buildings	-	344	335	348	353	328
Machinery	-	1,389	1,323	1,364	1,372	1,305
Construction In Progress	-	50	40	38	47	48
Order Backlog	-	478	468	782	736	581

Source: S&P Global Market Intelligence. Standard template. Financial Sources.